% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • chicagohpch chicagohpch Dec 22, 2009 9:39 PM Flag

    can someone shed some light on the options trade today

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Even MNKD gets FDA approval, the stock will likely to face a possible dilution of issuing new shares to raise funding.

      A GURU in the following article commented "GNBT may beat MNKD". Too much a risk. I would refer you a stock BCRX's chart to see the risk after FDA's approval.

      ---The Business of Diabetes: Generex vs. MannKind, Will Either Win?
      Earlier this week, Bennet Dunlap (YDMV) asked me to comment on a business story related to the debate over Generex' Oral-Lyn and MannKind's Afresa (see his post "FTNW: Oral/Inhaled Insulin"). Neither of these two products is on the market yet, but at least one opinionated writer, R.J. Steffens, posits that Generex is likely to be more successful than MannKind's Afresa. (see that article here). His logic, explained in the article, is based largely on the FDA, but he does little to comment on the logic based on the soundness of either company's business strategy.

      I commented on Bennet's post, but I really didn't have sufficient space in a comment to do this topic justice, as this really more of a business review of the insulin market, thus my latest "Business of Diabetes" posting.

      First for some relevant background, you may wish to catch Amy's recent interview with MannKind's chief, Alfred Mann. Amy closes with an appropriate question: Afresa: Dreamboat or shipwreck? She also appropriately notes that "only time will tell". Amen to that.

5.250.00(0.00%)Jul 7 4:00 PMEDT